On March 3, the Food and Drug Administration issued warning letters to thirty telehealth companies for marketing compounded versions of GLP-1 weight-loss drugs in ways the agency described as "false or misleading." The primary violations: implying the compounded products were equivalent to FDA-approved drugs like Ozempic and Wegovy, and obscuring that the products were not manufactured under FDA oversight. The letters threatened legal action, including potential seizure, without further notice. [1][2]

The warnings did not arrive in a vacuum. They came at the end of a months-long campaign the FDA had been telegraphing since February, when the agency announced its intent to take action against non-FDA-approved GLP-1 drugs. They came after Novo Nordisk had already declared that semaglutide — the active compound in Ozempic and Wegovy — was no longer in shortage, removing the regulatory carve-out that had permitted compounding pharmacies to produce it legally. And they came after Novo Nordisk sued Hims and Hers Health in February over a $49-a-month compounded semaglutide product that the company had launched, briefly, before pulling. [1][3]

That lawsuit ended on March 9, when Novo Nordisk dropped the case and entered a distribution agreement with Hims and Hers that will allow the telehealth company to sell FDA-approved Novo products. The denouement was less a victory for either side than a settlement of the old terms before the new regulatory environment could make the old terms irrelevant. [3]

The clinical facts the FDA cited are worth examining without reference to the financial stakes. Compounded drugs are not subject to the same manufacturing controls as FDA-approved products. They may contain incorrect dosages, incorrect ingredients, or contaminants introduced in less-regulated production environments. In the specific case of semaglutide, the concern is not abstract: GLP-1 agonists are injectable drugs with narrow therapeutic windows. The difference between the correct dose and too much is not trivial when the drug operates on the cardiovascular system. [2][4]

Those facts do not resolve the access question, which is the one the FDA's critics find more morally urgent. FDA-approved semaglutide costs approximately $1,300 a month without insurance. Compounded versions were available for $49 to $199 a month. For the 41 percent of American adults who meet the clinical criteria for obesity treatment and do not have comprehensive drug coverage, that gap is not a consumer preference — it is a structural barrier to treatment. The FDA's crackdown, whatever its public health justifications, removes the most affordable option in the market at a moment when the branded version remains inaccessible to most of the people who need it. [2][3]

STAT News reported on March 12 that the FDA's warning letters targeted a mix of large telehealth platforms and smaller direct-to-consumer prescription services. Hims and Hers received a letter; so did Try Nova, GLP-1 Solution, and approximately 27 other companies whose names have not all been made public. The letters gave companies ten business days to respond with their plans for compliance. [4]

The X community that has built around GLP-1 access advocacy — a surprisingly large and organized coalition of patients, pharmacists, and health tech entrepreneurs — does not dispute the FDA's authority to set manufacturing standards. What it disputes is the timing. The warning letters arrived precisely as the shortage designation that permitted compounding was formally lifted, closing the window before affordable alternatives had time to mature into a regulated market. The sequence looks, from the outside, like it was designed to protect Novo Nordisk's pricing power rather than to protect patients from unsafe drugs. [2]

The FDA's response to this framing, implicit in its public communications, is that compounding pharmacies are not a regulated market in any meaningful sense and cannot be made into one without fundamental changes to the Federal Food, Drug, and Cosmetic Act. That is true. It is also not the argument the agency usually makes when it warns companies — it warns them because they broke rules, not because the rules are correct. [1]

The thirty companies have until mid-March to comply or face enforcement. Most will comply. Compliance means stopping the marketing claims, not necessarily stopping the products, which is a distinction that will require further litigation to resolve. [1][4]

The underlying question — whether a drug system built around brand exclusivity can produce equitable access to medically significant obesity treatment — is not one the FDA's warning letters can answer. The letters can stop the misleading claims. They cannot make Wegovy affordable.

-- NORA WHITFIELD, Boston